安进Amgen Inc. (AMGN) 2016年年度报告「NASDAQ」.pdf

1、Dear Shareholders,In this letter,I would like to do two things.First,I would like to provide you with an assessment of Amgens performance for 2016.Second,since Amgens business of discovering,developing and delivering medicines that address significant unmet needs for patients with serious diseases i

2、s an inherently long-cycle onegenerally characterized by decades-long product cycles I would also like to update you on the progress we are making with our long-term objectives.A Snapshot of Amgens Strong 2016 PerformanceFor Amgen,2016 was a strong year in which we exceeded our expectations by achie

3、ving record results in revenues,earnings and cash flow with continued solid execution across the business.Our ability to achieve these results in the face of rapidly changing industry and competitive dynamics testifies to the effectiveness of our strategy.Importantly,through 2016,we remained squarel

4、y on track with our long-term strategy for growth and,in particular,on our trajectory to meet or exceed the 2018 commitments we made to shareholders back in 2014.2016 was also a year in which we began a necessary pivot into a new business cycle for Amgena cycle featuring branded and non-branded comp

5、etition for some of our mature medicines and an unprecedented set of new Amgen product offerings.We achieved 94 product/country approvals in 2016.These product launches were aligned with Amgens mission and strategy of serving patients suffering from serious illness and,in many cases,brought importan

6、t new medicines to underserved geographies.The strength of our product portfolio was reflected in 6 percent revenue growth in 2016,to a record$23 billion.The company-wide transformation efforts that we proactively began four years ago continued to bear fruit,helping us to achieve 12 percent non-GAAP